Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 10/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.35 |
| ▸ | ITGAL | P20701 | 2/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243514 | 0.89 | UTS2R (0.40) | UTS2RLMNA | |
| SCHEMBL3237990 | 0.83 | L3MBTL1 (0.47) | L3MBTL1SLC6A9ITGB2ICAM1ITGAL | |
| SCHEMBL3237956 | 0.82 | L3MBTL1 (0.46) | L3MBTL1SLC6A9ITGB2ICAM1ITGAL | |
| SCHEMBL3239756 | 0.79 | CTSS (0.48) | SLC6A9 | |
| SCHEMBL3907148 | 0.77 | SLC6A9 (0.47) | L3MBTL1SLC6A9ITGB2ICAM1ITGAL | |
| SCHEMBL4358876 | 0.76 | TACR3 (0.47) | — | |
| SCHEMBL3240255 | 0.75 | UTS2R (0.49) | L3MBTL1SLC6A9ITGB2ICAM1ITGAL | |
| SCHEMBL3238502 | 0.74 | L3MBTL1 (0.47) | L3MBTL1SLC6A9ITGB2ICAM1ITGAL | |
| SCHEMBL3238003 | 0.71 | UTS2R (0.47) | UTS2RLMNA | |
| SCHEMBL3905138 | 0.71 | ATM (0.44) | L3MBTL1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | L3MBTL1 3944/4885SLC6A9 13/4885ITGB2 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.